New drug combo aims to make stem cell transplants safer for blood cancer patients
NCT ID NCT06731504
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests whether adding abatacept to standard anti-rejection drugs can safely prevent graft-versus-host disease (GVHD) in 10 adults with blood cancers receiving a special type of stem cell transplant (omidubicel). Participants will receive the drug combination and be monitored for side effects and transplant success over 18 months. The goal is to see if this approach is safe and feasible before larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke University Health System
RECRUITINGDurham, North Carolina, 27705, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can specially trained immune cells flush out hidden HIV?
- Frailty check may steer safer cancer care for seniors
- Could gratitude exercises aid blood cancer recovery?
- Can a new tracer light up cancer growth?
- Could a walk a day keep brain fog away after a stem cell transplant?
- Could End-of-Life care for blood cancer patients be done at home?